ISOPLEXIS platform for single cell multiplexed functional proteomics of immune cells

Grant number: 223814/Z/21/Z

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2024
  • Known Financial Commitments (USD)

    $144,590.33
  • Funder

    Wellcome Trust
  • Principal Investigator

    Dr. Claire Roddie
  • Research Location

    United Kingdom
  • Lead Research Institution

    University College London
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The IsoPlexis IsoLight platform is a unique, highly multiplexed single-cell microchip proteomics technology applicable to both basic and clinical research. Quantitative measurement of secreted proteins associated with a broad range of functional profiles is derived from over 1000 live single cells using intracellular protein detection via high-density antibody barcode arrays. It can precisely dissect the functional heterogeneity ('polyfunctionality') of immune cells with genetically and phenotypically identical signatures and several studies have shown that polyfunctionality determined at the single-cell level can identify critical effector cells associated with durable immunity against infections and cancer. Isoplexis analysis of polyfunctionality in the cell therapy space reveals that phenotypically similar T-cells can have heterogeneous functions and that the 'polyfunctionality index' can provide predictive signatures for toxicity and response to treatment. This state-of-the-art equipment will be housed at the UCL Royal Free Campus and will be used primarily for disease-focused and translational immunology research spanning the disciplines of immunotherapy, autoimmmunity, immunodeficiency, infection (including COVID-19) and cancer. This breakthrough single cell proteomics analysis platform will enable immunology and immunotherapy scientists at UCL to further enhance their understanding of endogenous and engineered human immune cells subsets in the pathophysiology of disease and in the response to treatment.